Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12526123 | 0.86 | GRM5 (0.64) | GRM5CYP11B2IRAK4PDE10ASYK | |
| SCHEMBL18291839 | 0.85 | GRM5 (0.62) | GRM5CYP11B2IRAK4PDE10AMGLL | |
| SCHEMBL2459912 | 0.82 | GRM5 (0.60) | GRM5CYP11B2IRAK4PDE10A | |
| SCHEMBL15520747 | 0.80 | GRM5 (0.56) | GRM5CYP11B2IRAK4MGLLCYP11B1 | |
| SCHEMBL15889737 | 0.78 | GRM5 (0.65) | GRM5CYP11B2IRAK4PDE10AMGLL | |
| SCHEMBL46326 | 0.78 | GRM5 (0.57) | GRM5CYP11B2IRAK4MGLLSYK | |
| SCHEMBL1053384 | 0.76 | GRM5 (0.56) | GRM5CYP11B2IRAK4MGLLSYK | |
| SCHEMBL2398608 | 0.76 | GRM5 (0.56) | GRM5CYP11B2IRAK4MGLLSYK | |
| SCHEMBL18307164 | 0.76 | GRM5 (0.56) | GRM5CYP11B2IRAK4MGLLSYK | |
| SCHEMBL3663437 | 0.76 | GRM5 (0.52) | GRM5CYP11B2IRAK4MGLLCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475262-B1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |